Background: Imaging studies in Alzheimer’s disease (AD) have yet to answer the underlying questions concerning the relationship among tau retention, neuroinflammation, network disruption and cognitive decline. We compared the spatial retention patterns of 18F-THK5351 and resting state network (RSN) disruption in patients with early AD and healthy controls.Methods: We enrolled 23 11C-Pittsburgh compound B (PiB)-positive patients with early AD and 24 11C-PiB-negative participants as healthy controls. All participants underwent resting state functional MRI and 18F-THK5351 PET scans. We used scaled subprofile modeling/principal component analysis (SSM/PCA) to reduce the complexity of multivariate data and to identify patterns that exhibited the...
PURPOSE:To assess the in vivo whole-brain relationship between uptake of [18F]THK-5351 on PET and co...
The posteromedial cortex (PMC) is a key region involved in the development and progression of Alzhei...
In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progressio...
Background: Imaging studies in Alzheimer’s disease (AD) have yet to answer the underlying questions ...
PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET trac...
SEE SARAZIN ET AL DOI101093/BRAIN/AWW041 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The advent of ...
In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline. Preclinic...
PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET trac...
Objective: To investigate the characteristics of tau deposition and its impact on functional connect...
Purpose: We aimed to investigate associations between tau pathology and relative cerebral blood flow...
Tau pathology and neuroinflammation are key etio-pathogenetic mediators of Alzheimer’s disease (AD)....
Background: Integrity of functional brain networks is closely associated with maintained cognitive p...
In Alzheimer’s diseases (AD), tau pathology is strongly associated with cognitive decline. Preclinic...
As a central hub in the interconnected brain network, the precuneus has been reported showing disrup...
Alzheimer’s disease (AD) is the most common form of dementia, with no cure to stop its progression. ...
PURPOSE:To assess the in vivo whole-brain relationship between uptake of [18F]THK-5351 on PET and co...
The posteromedial cortex (PMC) is a key region involved in the development and progression of Alzhei...
In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progressio...
Background: Imaging studies in Alzheimer’s disease (AD) have yet to answer the underlying questions ...
PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET trac...
SEE SARAZIN ET AL DOI101093/BRAIN/AWW041 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The advent of ...
In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline. Preclinic...
PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET trac...
Objective: To investigate the characteristics of tau deposition and its impact on functional connect...
Purpose: We aimed to investigate associations between tau pathology and relative cerebral blood flow...
Tau pathology and neuroinflammation are key etio-pathogenetic mediators of Alzheimer’s disease (AD)....
Background: Integrity of functional brain networks is closely associated with maintained cognitive p...
In Alzheimer’s diseases (AD), tau pathology is strongly associated with cognitive decline. Preclinic...
As a central hub in the interconnected brain network, the precuneus has been reported showing disrup...
Alzheimer’s disease (AD) is the most common form of dementia, with no cure to stop its progression. ...
PURPOSE:To assess the in vivo whole-brain relationship between uptake of [18F]THK-5351 on PET and co...
The posteromedial cortex (PMC) is a key region involved in the development and progression of Alzhei...
In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progressio...